Abstract
Autologous stem cell transplantation after high-dose melphalan for the treatment with multiple myeloma has resulted in prolonged progression-free survival and overall survival in patients under 65 years. We have examined the role of autologous transplantation in 17 patients with multiple myeloma over 65 years at our centre using a matched pair analysis with younger patients. The median age of this cohort of patients over 65 years was 67 years (65–74) and their outcome and transplant-related morbidity was compared with 17 younger pair mates with a median age of 55 years (31–64). Sixteen patients received high-dose melphalan, and one received busulphan with autologous stem cell rescue. The high-dose therapy was well tolerated in both elderly patients and the matched pairs, with comparable time to recover neutrophils and platelets. Treatment-related mortality also did not differ significantly in both the groups. Median overall survival of the elderly patients was 3.59 years similar to 3.01 years of the pair mates (P = 0.92). Autologous stem cell transplantation after high-dose melphalan conditioning was equally well tolerated in groups of patients above and below 65 years. There was no difference in relapse rate, OS and myelotoxicity in both the groups. These findings suggest that advanced age should not be an exclusion criterion from autologous transplant programmes. Bone Marrow Transplantation (2000) 25, 533–539.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Group MTC . Combination chemotherapy vs mephalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials J Clin Oncol 1998 16: 3832–3842
ONS Monitor MB1 98/2 . Estimates of newly diagnosed cases of cancer, England and Wales 1993–1997
ONS Cancer Statistics: Registrations 1992 MB1 No. 25
Cunningham D, Paz A-L, Gore ME et al. High dose melphalan for multiple myeloma: long-term follow-up data J Clin Oncol 1994 12: 764–768
Cunningham D, Paz A-L, Milan S et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previous untreated myeloma J Clin Oncol 1994 12: 759–763
Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55–65
Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome (see comments) New Engl J Med 1996 335: 91–97
Powles R, Raje N, Milan S et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment Bone Marrow Transplant 1997 20: 435–443
Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma Blood 1999 93: 51–54
MacLennan IC, Chapman C, Dunn J, Kelly K . Combined chemotherapy with ABCM vs melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults Lancet 1992 339: 200–205
Raje N, Powles R, Kulkarni S et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma Br J Haematol 1997 97: 153–160
Raje N, Powles R, Horton C et al. Comparison of marrow vs blood derived stem cells for autografting in previously untreated multiple myeloma Br J Cancer 1997 75: 1684–1689
Ramiah V, Powles R, Sumpter K et al. A randomised trial of short course consolidation chemotherapy (MRC UKALL X) following high-dose chemotherapy in multiple myeloma Blood 1997 90: (Suppl.) 407b
Cunningham D, Powles RL, Malpas JS et al. A randomised trial of maintenance therapy with Intron-A following high-dose melphalan and ABMT in myeloma Br J Cancer 1993 67: (Suppl.) 30
Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results Br J Haematol 1998 102: 495–502
Gore ME, Selby PJ, Viner C et al. Intensive treatment of multiple myeloma and criteria for complete remission Lancet 1989 2: 879–881
Karinkanta HH, Nieminen EJ . An improved technique for immunofixation of electropherograms Clin Chem 1978 24: 1639–1641
Kohn J, Riches PG . A cellulose acetate immuno-fixation technique J Immunol Meth 1978 20: 325–331
Kruskal WH, Wallis WA . Use of ranks in one-criterian variance analysis J Am Stat Assoc 1952 47: 583–621
Kaplan EL, Meier P . Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples Br J Cancer 1972 35: 1–39
Smith H, Kark JD, Cassel JC, Sprears GFS . Analysis of prospective epidemiologic studies by minimum distance case-control matching Am J Epidemiol 1997 105: 567–574
Jagannath S, Vesole DH, Zhang M et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma Bone Marrow Transplant 1997 20: 445–450
Clavio M, Casciaro S, Gatti AM et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients Haematologica 1996 81: 238–244
Palumbo A, Triolo S, Argentino C et al. Melphalan at 100 mg/m2 with stem cell support is superior to standard treatment in multiple myeloma: a retrospective case-matched analysis Blood 1998 92: (Suppl.) 2732
Henon P, Donatini B, Eisenmann JC et al. Comparative survival, quality of life and cost effectiveness of intensive therapy with autologous blood stem cell transplantation or conventional chemotherapy in multiple myeloma Bone Marrow Transplant 1995 16: 19–25
Acknowledgements
We thank the Bud Flanagan Leukaemia Fund, the Cancer Research Campaign, the Institute of Cancer Research and the David Adams Leukaemia Fund.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sirohi, B., Powles, R., Treleaven, J. et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 25, 533–539 (2000). https://doi.org/10.1038/sj.bmt.1702188
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702188
Keywords
This article is cited by
-
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma
Bone Marrow Transplantation (2021)
-
Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study
International Journal of Hematology (2020)
-
Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
Annals of Hematology (2019)
-
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Bone Marrow Transplantation (2019)
-
Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study
Annals of Hematology (2017)